Newsroom

Direct Biologics, LLC Announces One Year Follow Up of Pilot Safety Study of ExoFlo for Treatment of Osteoarthritis in Combat-Related Injuries Thirty-three Navy SEAL veterans… Read More »Direct Biologics, LLC Announces One Year Follow Up of Pilot Safety Study of ExoFlo for Treatment of Osteoarthritis in Combat-Related Injuries

Direct Biologics Granted FDA Approval of Third IND Application for the use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy Extracellular vesicle product ExoFlo clinical trials… Read More »Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome

Direct Biologics Granted FDA Approval of Third IND Application for the use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy Extracellular vesicle product ExoFlo clinical trials… Read More »Direct Biologics Granted FDA Approval for Third IND Application to Investigate the use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy

Direct Biologics Receives FDA Approval to Proceed with Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome Extracellular Vesicle Isolate Product ExoFlo Shows… Read More »Direct Biologics Receives FDA Approval to Proceed with Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome

Innovative Product ExoFlo™ From Direct Biologics Fulfills Unmet but Urgent Medical Need in COVID-19 Treatment Medical professionals report dramatic and consistent success in treating patients… Read More »Innovative Product ExoFlo™ From Direct Biologics Fulfills Unmet but Urgent Medical Need in COVID-19 Treatment

Direct Biologics Announces New Advanced Tool in Regenerative Medicine with Launch of AmnioWrap™ Placental Allograft New Allograft Joins Market Leading ExoFlo™ Extracellular Vesicles in Direct… Read More »Direct Biologics Announces New Advanced Tool in Regenerative Medicine with Launch of AmnioWrap™ Placental Allograft

Direct Biologics Announces First Patient Treated Under Phase II Expanded Access Protocol Using ExoFlo™ to Treat COVID-19 The expanded Access Program provides a pathway for… Read More »Direct Biologics Announces First Patient Treated Under Phase II Expanded Access Protocol Using ExoFlo™ to Treat COVID-19

Direct Biologics Granted Expanded Access by FDA for ExoFlo™ in the Treatment of COVID-19 AUSTIN, Texas, October 13, 2020 (Newswire.com)Direct Biologics, LLC announced the launch… Read More »Direct Biologics Granted Expanded Access by FDA for ExoFlo™ in the Treatment of COVID-19

Direct Biologics Initiates Patient Enrollment in the Phase II EXIT COVID-19 Clinical Trial AUSTIN, Texas, September 9, 2020 (Newswire.com) Direct Biologics, LLC announced the launch… Read More »Direct Biologics Initiates Patient Enrollment in the Phase II EXIT COVID-19 Clinical Trial

Direct Biologics Receives FDA Approval to Initiate ‘EXIT-COVID-19,’ a Phase II Investigational New Drug Trial AUSTIN, Texas, July 29, 2020 (Newswire.com) Direct Biologics, LLC, is… Read More »Direct Biologics Receives FDA Approval to Initiate ‘EXIT-COVID-19,’ a Phase II Investigational New Drug Trial